Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. by Chen, Chi-Long et al.
JOURNAL OF VIROLOGY, OCt. 1993, p. 6303-6308 Vol. 67, No. 10
0022-538X/93/106303-06$02.00/0
Copyright C 1993, American Society for Microbiology
Epstein-Barr Virus (EBV) Gene Expression in EBV-Positive
Peripheral T-Cell Lymphomas
CHI-LONG CHEN,12 ROBERT H. SADLER,' DENNIS M. WALLING,' IH-JEN SU,2
HONG CHUNG HSIEH,2 NANCY RAAB TRAUBl*
Lineberger Comprehensive Cancer Center, University ofNorth Carolina at Chapel Hill, Chapel Hill,
North Carolina 27599-7295,1 and Department ofPathology, College of Medicine,
National Taiwan University, Taipei, Taiwan, Republic of China2
Received 16 February 1993/Accepted 28 June 1993
Epstein-Barr virus (EBV) DNA has been detected in peripheral T-celi lymphomas. In this study, analysis of
the EBV termini indicated that the infection was clonal and nonpermissive. Analysis of viral expression
detected the processed, spliced mRNAs representing EBNA1, LMP1, LMP2, and BamHI A transcripts in all
EBV-positive peripheral T-cell lymphomas. The LMP1 protein was detected by immunofluorescence in a single
specimen. In contrast, neither the EBNA2 protein nor the spliced EBNA2 mRNA were detected. These data
indicate that EBV-infected T-cell lymphomas are clonal expansions of a single EBV-infected cell with a pattern
of gene expression which is distinct from that detected in Burkitt's lymphomas or posttransplant lymphomas
but similar to viral expression in nasopharyngeal carcinomas.
Epstein-Barr virus (EBV) is the cause of infectious mono-
nucleosis and posttransplant lymphoma and is associated
with African Burkitt's lymphoma and nasopharyngeal carci-
noma (NPC) (6, 19, 20). EBV has also been detected in
Hodgkin's disease and in peripheral T-cell lymphoma (PTL)
(9, 11, 29, 30). Analysis of the EBV termini suggests that
most of these malignancies are clonal expansions of a single
EBV-infected cell (11, 19, 32). The evolution of malignancy
in a cell infected with a virus capable of inducing cellular
proliferation suggests that the virus is an important determi-
nant of the malignant pathway. Therefore, it is important to
compare patterns of viral expression in these distinct malig-
nancies.
Studies of viral infection in vitro have identified nine viral
proteins which are expressed in latently infected cells,
including six nuclear antigens (EBNAs) and three latent
membrane proteins (LMPs) (12). Several studies have char-
acterized viral expression in various human malignancies by
using human sera or monoclonal antibodies (MAbs). These
studies have identified several differences in viral expres-
sion. In Burkitt's lymphomas, only EBNA1 is believed to be
expressed, whereas in posttransplant lymphomas, EBNA1,
EBNA2, and LMP1 have been detected (23, 33). In NPCs,
EBNA1, LMP1, and LMP2 and a family of transcripts from
the BamHI A fragment are expressed (3, 4, 7, 8, 10). In
Hodgkin's disease, LMP1 and the EBV replication activator
protein, ZEBRA, have been detected in Reed-Sternberg
cells (16, 17). Detection of LMP1 and EBNA2 in several
cases of midline granuloma histologically characterized as
PTL has also been reported (9).
In this study, EBV infection in PTL was further charac-
terized by analysis of viral expression by using immunoflu-
orescence with monoclonal antibodies to LMP1 and EBNA2
and polymerase chain reaction (PCR) amplification of
cDNA. Tumor samples from six patients with histopatholog-
ically and phenotypically characterized PTL were obtained
from National Taiwan University Hospital. The histopatho-
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logic and immunophenotypic characteristics have been pre-
viously described (29, 30).
To identify and characterize EBV DNA in PTLs, South-
em blots were prepared with dilutions of Raji DNA repre-
senting approximately 1, 5, and 50 copies of episomal DNA
and sample DNA, digested with BamHI. Hybridization with
the XhoI a fragment, representing unique DNA adjacent to
the right terminus of EBV, identified a single EBV DNA
restriction enzyme fragment at a low copy number in spec-
imens 2 and 4 (Fig. 1 and Table 1). The low level of EBV
DNA in specimen 2 may reflect dilution of tumor tissue by
infiltrating cells or normal tissue. However, in other hybrid-
izations, approximately two genome copies were detected in
specimens 2 and 1 (data not shown). A single restriction
enzyme fragment was detected in each of the EBV-positive
PTLs. The same fragment was also detected by hybridiza-
tion with the EcoRI I fragment representing unique DNA
adjacent to the terminal repeats at the left end of the genome
(data not shown). The detection of a single fused restriction
enzyme fragment representing the fused EBV termini of the
episome indicates that a PTL is a clonal proliferation of a
single EBV-infected cell. Ladder arrays of smaller terminal
fragments representing virion DNA were not detected, indi-
cating that the EBV infection in PTLs was predominantly
latent. In contrast, in NPCs, abundant EBV DNA was
detected with additional heterogeneous smaller fragments
possibly representing linear DNA (Fig. 1). This suggests
that, in some cells in NPCs from Taiwan, EBV replicates,
resulting in an increase in the abundance of EBV DNA.
Two types of EBV have been defined by divergent se-
quences within the EBNA2 and EBNA3 genes (2, 5, 27). To
identify the EBV types in PTLs, a Southern blot was
hybridized to probes which distinguish the EBNA2 se-
quences (2, 35). Hybridization with the EBV1 and EBV2
EBNA probes to DNA from three EBV-positive specimens
identified EBV2 in specimen 1 and EBV1 in specimens 2 and
4 (Table 1). The detection of EBV2 in a Taiwanese PTL was
unexpected, as a similar analysis of Taiwanese NPCs iden-
tified the EBV1 strain in 10 of 10 specimens. The EBV1
strain detected in both PTLs and NPCs contains the restric-
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FIG. 1. Identification of EBV DNA in PTLs. Hybridization to
Southern blots prepared with DNA digested with BamHI from PTLs
and NPCs with an XhoI a RNA probe identified a single fragment in
PTL samples 2 and 4. EBV DNA was not detected in samples 5 and
6. Dilutions of Raji DNA representing 50 copies, 5 copies, or 1 copy
of EBV were included as positive controls.
tion enzyme polymorphisms characteristic of the Chinese
strain (data not shown) (1, 14).
To assess viral expression, frozen sections were stained
with MAbs specific for LMP1, CS1-4 and S12, and a MAb
for EBNA2, PE2 (15, 33, 34). LMP1 was detected with the
characteristic capping in the membrane in the positive con-
trol lymphoid cell line, BHM, which was established by
infection with B95-8 virus (Fig. 2A). In contrast, in the PTL,
the staining pattern was punctate throughout the membrane
and cytoplasm (Fig. 2B). The PE2 MAb detects an epitope
which is present in EBNA2 in both EBV1 and EBV2 (33).
Although EBNA2 was readily detected in the lymphoid and
Burkitt's lymphoma cell lines used as positive controls,
EBNA2 was not detected in any cells within the EBV-
positive PTLs (data not shown).
S1 nuclease analysis and cDNA cloning have revealed that
the EBV latent mRNAs are intricately spliced with long,
spliced, untranslated leader sequences (12, 25). The individ-
ual mRNAs can therefore be identified by amplification
across the specific splice into the coding sequences. EBV
transcription was analyzed by reverse transcriptase-based
PCR with five of the six PTLs. PTL 3 was not analyzed
because of the limited biopsy sample size.
The EBNA1 protein is required for replication of the EBV
episome and has been detected in all EBV-positive cell lines
and associated malignancies. At least three promoters which
are used in various states of infection for EBNA1 transcrip-
tion have been identified (3, 24, 25). Regardless of promoter
usage, all EBNA1 cDNAs which have been described con-
tain an exon within the BamHI U fragment (24, 25). The
ability to detect the EBNA1 mRNA was therefore used as a
marker for RNA integrity and the ability to detect low-copy-
number mRNAs. For all PCR analyses, equal aliquots of
RNA were used to prepare cDNA with or without reverse
transcriptase. The spliced mRNA encoding EBNA1 was
amplified with primers representing exons in BamHI U and
BamHI K, generating a 216-bp product representing the
mRNA (Fig. 3A). The 40-kb intron between these exons
inhibits amplification of genomic DNA or unprocessed tran-
scription, thus increasing the sensitivity of detection by PCR
(25). After gel electrophoresis and transfer to nitrocellulose,
the blot was hybridized to an EBNA1-specific oligonucleo-
tide probe. The EBNA1 mRNA was detected in the three
EBV-positive specimens which were tested (specimens 1, 2,
and 4) but was not detected in the two examples of EBV-
negative T-cell lymphoma (specimens 5 and 6).
The EBNA2 mRNA was amplified with primers within the
Y2 exon to primers within the YH exon, which contains
the coding open reading frame (2). The spliced cDNA
and genomic DNA PCR products are 209 and 595 bp long,
respectively. Although the 209-bp product representing
EBNA2 mRNA was readily detected in the cDNA prepara-
tion from the B95-8 lymphoid cell line, the spliced product
representing the EBNA2 mRNA was not detected in any of
the T-cell lymphoma specimens (Fig. 3B).
Strains with the EBNA2 gene deleted have been found in
cell lines maintained in vitro, in samples from normal indi-
viduals in vivo, and in hairy leukoplakia specimens (5, 21,
28, 31). To confirm that the EBV strains in PTLs contained
the EBNA2 coding sequences, DNA was amplified with a set
of primers which span the EBNA2 open reading frame
(Table 2). The 1.4-kb fragment representing the intact
EBNA2 open reading frame was detected in the EBV-
positive samples (specimens 1, 2, and 3), indicating that
TABLE 1. PCR analysis of EBV gene expression in PTLs
EBV Detection of protein Detection of mRNA by RT-PCR'Case D by IFb
LMP1 EBNA2 EBNA1 EBNA2 LMP1 LMP2A LMP2B BAd
1 + (2) + - + - + + - +
2 + (1) - - + - + + - +
3 +* (ND)e - - ND ND ND ND ND ND
4 + (1) - - + - + + + +
5 +/ - - - - - +
6 - - - - _ _ _ _
a EBV DNA detection is indicated by + for positive hybridizations with the XhoI a probe, + * for detection by in situ hybridization (29), and +/- for detection
by PCR. The EBV type is given in parentheses.
b IF, immunofluorescence.
c RT-PCR, reverse transcriptase-based PCR amplification of cDNA.
d BA, BamHI A fragment.





FIG. 2. Identification of the LMP1 protein in PTLs. Frozen sections were fixed in a chilled 1:1 mixture of methanol and acetone and
stained with the S12 and CS1-4 MAbs for LMP1 and the PE2 MAb for EBNA2 and then with biotin-conjugated goat anti-mouse
immunoglobulin G antibody (Vector Laboratories, Burlingame, Calif.) and fluorescein avidin D (Vector) (15, 33, 34). EBV-positive (Raji,
B95-8, and BHM) and EBV-negative (BJAB and Louckes) lymphoblastoid cell lines were used as positive and negative controls. (A)
Detection of LMP1 with MAb CS1-4 in the lymphoblastoid cell line BHM identified the characteristic capped-membrane staining. (B) LMP1
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FIG. 3. Detection of EBV mRNA in PTLs by reverse transcriptase-based PCR. cDNA was synthesized and PCR amplification was
performed as described previously with equal aliquots for reactions with (RT+) or without (RT-) reverse transcriptase (5). Controls
containing all PCR reagents and containing H20 instead of the template were included for all reactions (H20). The oligonucleotides (arrow)
used for PCR which spanned the specific introns for the EBNA1, EBNA2, LMP1, LMP2A, LMP2B, and BamHI A transcripts are presented
in Table 2. The BamHI fragments and open reading frames are indicated. TR, terminal repeat. After transfer to nitrocellulose, the products
were hybridized with internal 32P-labeled oligonucleotide probes (Table 2). B95-8 cDNA was used as a positive control for PCR products
representing the processed mRNAs. HeLa cell cDNA was used as a negative control in LMP2 reactions. (A) Detection of EBNA1 mRNA
with primers from the BamHI U and BamHI K fragments in the B95-8 EBV genome. The PCR product representing the spliced mRNA of
EBNA1 is 216 bp long. (B) Analysis of EBNA2 mRNA transcription in PTLs. The PCR products of cDNA representing the spliced EBNA2
mRNA and of genomic DNA are 209 and 595 bp long, respectively. Transcription was not detected in the PTL samples, although the spliced
EBNA2 PCR product was readily detected with RNA from the B95-8 cell line. (C) Detection of LMP1 mRNA in PTLs. The sizes of the PCR
products representing spliced mRNA and genomic DNA of LMP1 are 296 and 450 bp long, respectively. The LMP1 mRNA was detected in
all EBV genome-positive samples. A PCR product representing EBV genomic sequences was detected in sample 5 with and without reverse
transcriptase. This result may reflect amplification of DNA from EBV-positive B lymphocytes. (D) Detection of LMP2 mRNA in PTLs. The
LMP2 mRNAs have distinct first exons. The PCR products for each mRNA utilized primers from the two distinct first exons and primers from
exon 2, generating products of 309 bp for LMP2A and 301 bp for LMP2B. The LMP2A mRNA was detected in the EBV-positive samples










TABLE 2. Sequences of oligonucleotide primers
Primer specificity B95-8 Primer sequence
EBNA1 67544-67563 5' AGAGAGTAGTCTCAGGGCAT 3'
108051-108032 5' TCTTCTTTGAGGTCCACTGC 3'
EBNA1 probe 107994-107975 5' TCCTAGGCCATTTCCAGGTC 3'
EBNA2 47940-47959 5' GCGCCAATCTGTCTACATAG 3'
48534-48515 5' CCCCATGTAACGCAAGATAG 3'
EBNA2 probe 48473-48454 5' CGGGTGCTTAGAAGGTTGTT 3'
EBNA2 open reading frame 48515-48538 5' CTATCTTGCGTTACATGGGGGACA 3'
49952-49932 5' GCGAGGTCTTTTACTGGGTCC 3'
LMP1 (external) 168666-168686 5' AGTTAGAGTCAGATTCATGGC 3'
169305-169285 5' CCTTTGCTCTCATGCTTATAA 3'
LMP1 (nested) 168813-168833 5' CAACCAATAGAGTCCACCAGT 3'
169263-169243 5' TCTTCAGAAGAGACCTTCTCT 3'
LMP1 probe 168888-168908 5' GGAAGAAGGCCAAAAGCTGCC 3'
LMP2A 166820-166840 5' GATTGCAACACGACGGGAATG 3'
LMP2B 169819-169839 5' CAGTGTAATCTGCACAAAGAG 3'
LMP2A and LMP2B 271-251 5' AAGTGACAACCGCAGTAAGCA 3'
LMP2 probe 229-249 5' AAACTGCTGACACCGGTGACA 3'
BamHI A (external) 159493-159512 5' CGCCCCCAGGTCTTGTTGTA 3'
160537-160518 5' AGCTCCTCTATTGGAACTCT 3'
BamHI A (nested) 159946-159974 5' GCCAGCTCCCAGTAGACCACGTCCCCCCA 3'
160266-160247 5' CACGGCGCACCCCCAGTACC 3'
BamHI A probe 160004-160023 5' TCTCGCTCTGTTGCGCCAGG 3'
EBNA2 was not deleted in the EBV strains in PTLs (data
not shown).
The LMP1 introns are relatively small and total 154 bp.
Amplification across these introns is less sensitive than that
across large introns; therefore, two nested pairs of primers
which generated a 450-bp genomic signal and a 296-bp
product representing the spliced mRNA were used. The
296-bp product representing the spliced form was detected in
specimens 1, 2, and 4 (Fig. 3C). The 450-bp PCR product
representing genomic DNA was detected in both the reverse
transcriptase-positive and -negative reaction mixtures for
specimen 5, indicating the presence of contaminating DNA.
As EBV DNA was not detected on Southern blots for
specimen 5, the detection of EBV by PCR for specimen 5
may represent amplification of DNA from infiltrating EBV-
positive B cells.
The detection of LMP1 mRNA in specimens 1, 2, and 4
with detection of protein only in specimen 1 may indicate
that the level of protein is undetectable in the other samples
or suggest that the LMP1 mRNA is not always translated.
Similar results have been reported for NPC (3, 34).
The spliced mRNAs encoding the LMP2A and LMP2B
proteins are transcribed across the terminal repeats (13, 26).
The two forms of the protein differ, as the first exon of the
LMP2A mRNA encodes a hydrophilic cytoplasmic domain
at the amino terminus while the first exon of LMP2B mRNA
is noncoding. Amplification with primers from the two
distinct first exons for LMP2A and LMP2B to primers in
exon 2 generates 309- and 301-bp products, respectively (4).
Like the EBNA1 mRNA, the large intron between the first
and second exons inhibits the amplification of genomic DNA
and unprocessed transcription. The LMP2A spliced product
was detected in the EBV-positive specimens 1, 2, and 4. The
LMP2B product was detected only in specimen 4. Interest-
ingly, the LMP2A product was also detected in specimen 5,
in which EBV DNA was only detectable by PCR (Fig. 3). In
a previous study, the LMP2AmRNA was the only transcript
detected by PCR in peripheral blood lymphocytes (18). Thus
the data presented here suggest that specimen 5 contained
EBV-positive lymphocytes which also expressed LMP2A.
Abundant transcription from the BamHI A fragment has
been consistently detected in NPCs. The cDNAs represent-
ing these transcripts are intricately spliced (7, 10). Am-
plimers which span a small 171-bp splice generate 150- and
321-bp products that are spliced and genomic products,
respectively (7). In all three of the EBV-positive specimens
(1, 2, and 4), the signals representing both the spliced and
unspliced forms were detected only in the reaction mix-
tures which contained reverse transcriptase (data not
shown). This result reveals the presence of both spliced
and unspliced transcription from these sequences in
PTLs.
In summary, the data presented here indicate that a PTL is
a clonal proliferation of a single EBV-infected cell, like other
malignancies associated with EBV. In addition, the absence
of small linear fragments detected by the assay used in this
study indicates that PTL is predominantly a latent infection.
The pattern of viral expression in PTL is distinct from that
which has been shown to occur in the B-cell malignancies
associated with EBV, Burkitt's lymphoma and posttrans-
plant lymphoma, and is similar to that detected in NPC with
consistent transcription of EBNA1, LMP1, LMP2A, and
BamHI A (4, 5, 7, 10). The absence of EBNA2 expression in
PTL, which is an additional example of EBV-infected lym-
phoid tissue, suggests that the expression of EBNA2 and the
coordinately regulated EBNA3 proteins is apparently B-cell
specific. Moreover, these similar patterns of expression in
two malignancies associated with EBV suggest that these
gene products either are essential for maintaining viral
infection or contribute to tumor growth and clonal predom-
inance.
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